Another patent for pSivida

GLOBAL nanotechnology company pSivida Limited’s UK operating subsidiary pSiMedica has been granted a further patent in the US market.

The patent provides for a method of implanting an electronic device within a living animal or human body, wherein the device includes bioactive silicon and a method of delivering a drug to a living animal or human by placing the drug to be delivered on or within a bioactive silicon structure.

pSivida managing director Gavin Rezos said the new US patent was an important addition to the company’s intellectual property portfolio.

"The patent will draw further attention in the US to the versatility of the BioSilicon technology platform and, in particular, to large value-adding electronics and chip companies looking to develop ‘smart’ devices with potential applications in controlled drug delivery and diagnostics.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
10th-The University of Notre Dame Australia6,708
47 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer